Study of genes and diet linked to stomach cancer risk
Part of Cancer, Digestive system clinical trials.
This study looks at how people’s genes and diet may relate to the chance of developing stomach (gastric) cancer. If you’re already enrolled in certain research groups, your existing data may be used to explore these risk patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be part of the StoP Project research collaboration
- You must be enrolled with UK Biobank
- You must be age 18 or older
- Your data set must include at least 80 confirmed stomach cancer cases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood that could show if someone is at risk for stomach cancer or pre-cancerous changes. It aims to help catch problems earlier.
This study collects health information from people at different stages of stomach cancer risk, including those with precancerous changes, healthy individuals, and those with early stomach cancer. The goal is to better understand and prevent stomach cancer.
This trial looks at tiny pieces of DNA found outside cells in stomach tissue to better understand how gastric (stomach) cancer starts and progresses. It may help future patients by improving how doctors study stomach cancer from biopsy and surgical samples.
This study looks for early warning changes in the stomach and aims to improve early detection and prevention. Depending on your situation, you may be grouped as having stomach symptoms, early lesions that might be removed, already-diagnosed stomach cancer, or a comparison group without stomach problems.
This study looks for metabolic markers in your blood and tumor tissue to help find stomach cancer early, predict your prognosis, and watch for recurrence. If you qualify, you would give blood and tumor samples for testing.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.